生物源
rabbit
品質等級
共軛
unconjugated
抗體表格
IgG fraction of antiserum
抗體產品種類
primary antibodies
無性繁殖
polyclonal
形狀
buffered aqueous solution
分子量
antigen approximately 57 kDa
物種活性
human
技術
microarray: suitable
western blot: 0.5 μg/mL using human HeLa cell extract
UniProt登錄號
運輸包裝
dry ice
儲存溫度
−20°C
基因資訊
human ... TNFRSF10A(8797)
一般說明
DR4, referred to as TRAIL Receptor-1, is a novel death domain containing receptor whose ligand has been identified as TRAIL or apoptosis-inducing ligand 2 (Apo2L). It is a member of the TNF superfamily of receptors that induce apoptosis. It is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine, and thymus.
免疫原
synthetic peptide corresponding to amino acids 1-20 of the N-terminal of the mature human DR4.
應用
Anti-DR4 antibody produced in rabbit is suitable for microarray and immunoblotting at a working dilution of 1:500-1:1000 using total HeLa, K562, and Jurkat whole cell lysates. It was used as a primary antibody in the immunodetection of DR4 in cell lysate of human small cell lung carcinoma cells. It was used as a primary antibody in the immunoblot analysis of fetal and adenocarcinoma epithelial colon cells in a study.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
生化／生理作用
DR4 induces apoptosis in a variety of human tumor cell lines, but not in normal cells and activates NF-κB.
外觀
Solution in phosphate buffered saline containing 0.02% sodium azide
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
10 - Combustible liquids
Lenka Kočí et al.
Cytokine, 55(1), 34-39 (2011-04-13)
The resistance of transformed epithelial cells to a detachment-induced apoptosis (anoikis) can significantly affect their susceptibility to anticancer therapy. We showed that detachment of both fetal (FHC) and adenocarcinoma (HT-29) human colon epithelial cells resulted in the activation of the
P Schneider et al.
Immunity, 7(6), 831-836 (1998-01-16)
TRAIL induces apoptosis through two closely related receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Here we show that TRAIL-R1 can associate with TRAIL-R2, suggesting that TRAIL may signal through heteroreceptor signaling complexes. Both TRAIL receptors bind the adaptor molecules FADD and
Alena Vaculova et al.
Molecular cancer, 9, 87-87 (2010-04-27)
TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a
S R Wiley et al.
Immunity, 3(6), 673-682 (1995-12-01)
A novel tumor necrosis factor (TNF) family member has been cloned and characterized. This protein, designated TNF-related apoptosis-inducing ligand (TRAIL), consists of 281 and 291 aa in the human and murine forms, respectively, which share 65% aa identity. TRAIL is
G Pan et al.
Science (New York, N.Y.), 276(5309), 111-113 (1997-04-04)
TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门